- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Erasmus University Rotterdam
Headquarters: Rotterdam, Netherlands
Website: http://www.eur.nl
Year Founded: 1913
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 9, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into infectious disease
Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery
BioCentury | Jun 4, 2021
Distillery Therapeutics
Inhibiting DDX3 to reverse HIV latency
DISEASE CATEGORY: Infectious disease
INDICATION: HIV/AIDS Inhibitors of RNA helicase DDX3 could serve as HIV latency reversal agents that could eliminate the viral reservoir by promoting apoptosis
INDICATION: HIV/AIDS Inhibitors of RNA helicase DDX3 could serve as HIV latency reversal agents that could eliminate the viral reservoir by promoting apoptosis
BioCentury | Feb 19, 2021
Translation in Brief
mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more
BioCentury’s roundup of translational news
BioCentury | Dec 2, 2020
Emerging Company Profile
Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets
Emerging Company Profile: Noema emerges from stealth with $59M to develop four clinical neurology programs in-licensed from Roche
BioCentury | May 20, 2017
Strategy
Henri: N of 1
How the late Genzyme CEO Henri Termeer created the Orphan drug industry
BioCentury | Apr 27, 2017
Targets & Mechanisms
Selective senescence
How targeting FOXO4 led to a selective peptide for senescence
BioCentury | Mar 28, 2017
Clinical News
Peptide kills senescent cells, reverses chemo toxicity in mice
Items per page:
1 - 10 of 21